NS 2359

Drug Profile

NS 2359

Alternative Names: 372475; GSK 372475; NS2359

Latest Information Update: 18 Jan 2017

Price : $50

At a glance

  • Originator NeuroSearch
  • Developer National Institute on Drug Abuse; Saniona; University of Pennsylvania
  • Class Antidepressants; Drug withdrawal therapies; Nootropics
  • Mechanism of Action Adrenergic receptor antagonists; Dopamine uptake inhibitors; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cocaine abuse
  • Discontinued Alcoholism; Attention-deficit hyperactivity disorder; Major depressive disorder

Most Recent Events

  • 01 May 2016 University of Pennsylvania initiates enrolment in a phase II trial for Cocaine abuse in USA (PO) (NCT02798627)
  • 16 Dec 2015 Saniona in collaboration with University of Pennsylvania plans a phase II trial for Cocaine abuse in USA
  • 13 Aug 2015 US FDA approves IND application for NS 2359 in Cocaine abuse
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top